XNAS · Healthcare · Biotechnology
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-04 | Q1 2026 | -0.10 | 0.05 | +150.00% | $127.2M | ✅ Beat | -0.58% | -3.12% | +0.65% |
| 2026-02-19 | Q4 2025 | 0.24 | 0.37 | +54.17% | $129.7M | ✅ Beat | -1.37% | +1.43% | -8.40% |
| 2025-10-30 |
| Q3 2025 |
| -0.17 |
| 0.59 |
| +447.06% |
| $164.9M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | -0.12 | 0.13 | +146.43% | $114.4M | ✅ Beat | +0.35% | +4.70% | +25.52% |
| 2025-02-20 | Q4 2024 | -0.38 | -0.47 | -23.68% | $74.8M | ❌ Miss | -6.79% | -12.47% | -9.71% |
| 2024-10-31 | Q3 2024 | -0.68 | -0.46 | +32.35% | $62.9M | ✅ Beat | +0.40% | +0.91% | +11.83% |
| 2024-08-01 | Q2 2024 | -0.86 | -0.65 | +24.42% | $52.2M | ✅ Beat | -2.60% | -7.68% | +3.90% |
| 2024-02-15 | Q4 2023 | -1.26 | -0.94 | +25.40% | $45.1M | ✅ Beat | -6.18% | -10.07% | -17.85% |
Showing last 8 quarters.